Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MVX ONCO 1

Drug Profile

MVX ONCO 1

Alternative Names: MaxiVax vaccine; MVX-1 loaded autologous tumour vaccine; MVX-1-loaded macrocapsule/autologous tumour cell vaccine - MaxiVax; MVX-ONCO-1

Latest Information Update: 06 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MaxiVax
  • Class Cancer vaccines; Cell therapies; Immunotherapies
  • Mechanism of Action Granulocyte-macrophage colony-stimulating factor expression stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Head and neck cancer

Most Recent Events

  • 20 Oct 2023 Safety and efficacy data from a phase II trial in Head and neck cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 29 Jun 2023 MaxiVax completed a phase-II trials in Head and neck cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease, Recurrent) in Switzerland (SC) (NCT02999646)
  • 10 Sep 2022 Final efficacy and adverse events data from a phase I trial in Solid tumours presented at the 47th European Society for Medical Oncology Congress(ESMO-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top